1.

Dang L. Osteoblastic PLEKHO1 contributes to joint inflammation in Rheumatoid Arthritis. The 39^th KCR Annual Scientific Meeting and the 13^th International Symposium (KCR 2019).Oral Presentation Abstracts. Travel Grant Award. May 16-18, 2019. Seoul, Korea.

2.

Ren Q. A potential next-generation sclerostin inhibitor specifically targets sclerostin monomer for bone anabolic therapy with low cardiovascular risk to reverse established osteoporosis in ovariectomized rats. The 39^th KCR Annual Scientific Meeting and the 13^th International Symposium (KCR 2019). Poster Presentation Abstracts. Travel Grant Award. May 16-18, 2019. Seoul, Korea. 

3.

Liu J. Unraveling the mystery behind bone-cartilage crosstalk: Osteoclast derived exosomal microRNAs deprive the resistance of cartilage to matrix degeneration, angiogenesis, and innervation in osteoarthritis. American Society for Bone and Mineral Research (ASBMR) 2019 annual meeting. Plenary Oral Presentation. 2019 ASBMR Young Investigator Award. September 19-23, 2019. Orlando, USA.

Award in 2018

Liang C. HIF1α inhibition facilitates Leflunomide suppressing CRP to attenuate progressive bone erosion in distinctive rheumatoid arthritis. The 9th International Conference on Osteoporosis and Bone Research (ICOBR2018). Oral Presentation Abstracts. Best Paper Award. October 17-20, 2018. Suzhou, China.

Zhang G. Mechanism of post-translational modification in protein homeostasis control. 2017 Beijing Science and Technology Award (First class). No.: 2017基-1-001-05. 

Liang C. Mechanism of post-translational modification in protein homeostasis control. 2017 Beijing Science and Technology Award (First class). No.: 2017基-1-001-06. 

Dang L. Research scholarship provided by the “Wai Tak Land Investment & Loan Co., Ltd.”, 2018.

Award in 2017

1.

Liang C, Peng S, Zhang BT, Lu Aiping, Zhang G. From precision medicine to drug discovery: inhibition of osteoblastic Smurf1 promotes bone formation in distinctive individuals with age-related osteoporosis. Webster Jee Young Investigator Award. 2017 ICMRS-ORS Membership Meeting, March 20, 2017. San Diego, California, USA.

2.

Yu Y, Li Y, Wu X, Li F, Lu A, Zhang G. An innovative gain-loss cell-SELEX strategy for development of a nucleic acid aptamer against PD-L1 for immunotherapy of triple negative breast cancer. Poster Abstract. Travel Award. Aptamer 2017, 11-12 April 2017. St. Hilda’s College, Oxford, UK.

3.

Dang L, Shaikh AB. Osteoblastic Plekho1 contributes to articular inflammation and bone repair failure in rheumatoid arthritis. The third prize. The National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competition 2017, May 22-23 2017. Hong Kong, China.

4.

Lu J, Li FF, Liu J. Develop a Highly Water Soluble Nucleolin Aptamer Paclitaxel Conjugate with a Cathepsin Labile Linker for Tumor Specific Targeting in Ovarian Cancer. The second prize.  "Entrepreneurship Challenge Cup" - the National Competition - Hong Kong Regional Final, May 22-23 , 2017, Hong Kong, China.

Dang L. Research scholarship provided by the “Wai Tak Land Investment & Loan Co., Ltd.”, 2017.

6.

LuJ, Li FF.Develop a Highly Water Soluble Nucleolin Aptamer Paclitaxel Conjugate with a Cathepsin Labile Linker for Tumor Specific Targeting in breast Cancer. The First Prize.The Fifteenth “Challenge Cup” National Final Competition. November 14-18, 2017, Shanghai, China.

7.

Dang L, Liu J. A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of MicroRNAs in Osteoclasts. The Third Prize.  The Fifteenth “Challenge Cup” National Final Competition. November 14-18, 2017, Shanghai, China.

Award in 2016

1.

Liang C, Lu Aiping, Zhang G. Oligopeptide aptamer-modified chalcone derivative specifically targets Smurf1 in osteoblasts and promotes bone formation. Oral Abstract. Travel Award. Aptamers 2016, 04-05 April 2016. Hilda’s College, Oxford, UK

2.

Liu J, Li D, Dang L, Lu A, Zhang G. miR-214-3p targets TRAF3 to promote osteoclastic bone resorption during the development of postmenopausal osteoporosis. ESCEO-AgNovos Healthcare Young Investigator Awards, World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, April 14 -17, 2016, Malaga, Spain.

3.

Dang L, Liu J, Li D.F. A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of MicroRNAs in Osteoclasts.1st Runner Up. "Entrepreneurship Challenge Cup" - China Competition - Hong Kong stage, 20-22 June, 2016, Hong Kong, China

4.

Wang L.Y., Liang C, Li F.F., Zhang G, Lu A.P. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGF-A in osteosarcoma. Oral Abstract. Webster Jee Travel Award, the 8th International Conference on Osteoporosis and Bone Research, 19-22 October, 2016, Chong Qing, China.

5.

Wu X.H., Liu   J, Xiao L.B., Lu A.P., Zhang G. Alterations of gut microbiome in rheumatoid arthritis. Oral Abstract. Webster Jee Travel Award, the 8th International Conference on Osteoporosis and Bone Research, 19-22 October, 2016, Chong Qing, China.

6.

Liang C, Peng S, Zhang BT, Lu Aiping, Zhang G. Inhibition of osteoblastic Smurf1 promotes bone formation in distinctive individuals with age-related osteoporosis. Oral   Abstract. Best Paper Award. 8th International Conference on Osteoporosis and Bone Research, October 19-22, 2016, Chongqing, China.

Award in 2015

1.

Liang C.One-year studentship provided by the “Mr. Kwok Yat Wai and Madam Kwok Chung Bo Fun Graduate School Development Fund”, 2015.

2.

Liang C, Guo B, Wu H, Zhang L, Lu A, Zhang G. Aptamer-functionalized delivery system for osteogenic siRNAs to achieve osteoblast-specific RNA interference for bone anabolic therapy. 2015 Orthopaedic Research Society (ORS) annual meeting, Las Vegas, March 28-31, 2015. Certificate.

3.

Liu J, Dang L, Li D, Guo B, Lu A, Zhang G. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of miRNAs in osteoclasts. Poster Abstract, Young Investigator Award, ICMRS Conference and Xiangya Osteoporosis Forum, Changsha, China, Apr 9-11, 2015. Certificate

4.

Liang C, Xu M, Xu J, Zhang B, Lu A, Zhang G. Discovery of Small Molecules to Promote BMP Signaling and Bone Formation. 6th Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM). Abstract. Clinical and Translational Medicine Excellent Thesis Awards.

5.

Liang C, ASBMR Young Investigator Award for the European Calcified Tissue Society (ECTS) Ph.D. Training Course. University of Siena, Tuscany, Italy. September 13-16, 2015.

6.

Li D.F., Liu J, Guo B.S., Dang L, Liang C, Liu B, He B, He X.J., Liang Z.C., Lu A.P., Zhang G. Osteoclast-derived exosomal miR-214 inhibits osteoblastic bone formation. ASBMR 2015 Annual Meeting. Oral Presentation. Abstract. Young Investigator Award. October 9-12, 2015.

7.

Liu J, Li D.F., Guo B.S., Dang L, Lu A.P., Zhang G. Osteoclastic miR-214 targets PTEN to increase bone resorption. ASBMR 2015 Annual Meeting. Plenary Poster. Abstract. Young Investigator Travel Grant. October 9-12,   2015.

Award in 2014

1.

Zhang Ge. Investigation of regulatory mechanism of ubiquitin   ligases and their  application in the treatment of osteoporosis. Chinese Medical Science and Technology Award. (Second class). 2014.

2.

Zhang Ge. Investigation of  molecular function, regulatory mechanism and disease correlation of ubiquitin ligases. Beijing Science and Technology Awards (First class). 2014. Certificate.

3.

Zhang Ge. Modernization of  traditional  anti-osteoporosis Chinese medicine. National Science & Technology Progress Award (Second class). 2014.  Certificate.

4.

Liang C, Guo B, Wu H, Zhang L, Lu A, Zhang G. Aptamer-Functionalized  Lipid Nanoparticles (LNPs) Targeting  Osteoblasts as a Novel RNA  Interference-Based Bone Anabolic Strategy.  ASBMR 2014 Annual Meeting. Oral  Presentation  Abstract. Young  Investigator Award. September   12-15,  2014.

5.

Liang C, Guo B, Wu H, Zhang L, Lu A, Zhang G. Aptamer-Functionalized  Lipid Nanoparticles   (LNPs) Targeting Osteoblasts as a Novel RNAi-Based Bone  Anabolic Strategy. 5th Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM). Abstract. Clinical and Translational Medicine  Excellent Thesis Awards.

6.

Dang L, Guo B, Li D, Lu A, Zhang G. A Peptide-functionalized delivery system to target   osteoclasts.  ASBMR 2014.  Poster Presentation Abstract. Young Investigator Travel Grant Award.  September 11-15, 2014.

7.

Baosheng Guo, Liu Jin, Dang  lei, Liang Chao, Xiaohua Pan,  Lingqiang Zhang, Aiping Lu, Baoting Zhang, Ge Zhang. Up-regulated CKIP-1 expression within osteoblasts associates with reduced BMP signaling and  decreased bone formation during aging, The excellent thesis award. The 5th Sino-American Symosium on Clinical and Translational Medicine, May 31, 2014, Beijing. Certificate.

8.

Liang C, Guo B, Wu H, Zhang L, Lu A, Zhang G.  Aptamer-Functionalized  Lipid  Nanoparticles (LNPs)   Targeting Osteoblasts  as a Novel RNAi-Based Bone  Anabolic Strategy. Webster Jee Travel Award. the 7^th  international  Conference on Osteoporosis and Bone Research, Oct 16-19,  Xiamen, China.

Award in 2013

1.

Jin Liu, Does  age-related increase in CKIP-1 within mesenchymal stem cells associate with  age-related impairment in fracture repair ?, Oral Presentation Award (2nd Prize), Postgraduate Research  Symposium on Regenerative Medicine 2013, Guangzhou, China, 2013. Certificate.

2.                      

Biao Liu, Toward  targeted therapy in advanced   pancreatic cancer: a smart triptolide-nucleolin aptamer conjugate, Oral Presentation  Award (3nd Prize),  Postgraduate Research Symposium on Regenerative  Medicine 2013, Guangzhou, China, 2013.  Certificate.